
IGC Stock Forecast & Price Target
IGC Analyst Ratings
Bulls say
IGC Pharma is a clinical-stage pharmaceutical company developing novel therapies to treat, cure, or prevent Alzheimer's disease. With a large market potential and upcoming milestones in mid-2026, as well as reported positive interim results in 2024 and strong fiscal performance, the company's focus on Alzheimer's disease presents high potential for investors. However, risks such as balance sheet and liquidity risks, failure to gain regulatory approvals, and competition must also be considered.
Bears say
IGC Pharma is an early/clinical stage drug development company with minimal revenue and a current focus on Alzheimer's disease, a progressive neurologic disease. While their recent interim results for their Phase 2 trial on IGC-AD1 show potential, the company still faces risks such as balance sheet/liquidity concerns and failure to gain regulatory approvals. Additionally, their current valuation may be attractive but is supported by assumptions and there is no guarantee of success.
This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.
IGC Analyst Forecast & Price Prediction
Start investing in IGC
Order type
Buy in
Order amount
Est. shares
0 shares